0

publications
en 2020

0

publications
en 2021

0

publications
en 2022

0

publications
en 2023

0

publications
en 2024

0

publications
en 2025

0

publications
en 2026

Selection for Function in Early Life: Implications for Early-Onset Pathologies

Abstract

Persistent pathological structures, such as tumors, fibrotic nodules, granulomas, microbial biofilms, or protein aggregates, are traditionally viewed as age-related conditions that emerge after reproduction, when natural selection is less effective at eliminating traits expressed late in life. However, some pathologies with robust and organized architectures can arise surprisingly early, challenging this classical perspective. We recently proposed that intra-organismal selection for function, a selective process operating within organisms and acting on non-reproducing entities by favoring structural configurations that enhance stability, robustness, and novelty generation, may play a role in aging. Here, we suggest that this same process can also operate well before the so-called selection shadow (i.e., life stages where natural selection is too weak to purge deleterious mutations). We identify three non-mutually exclusive mechanisms that may promote this early-life action: (i) initial local adaptive benefits, such as improved tissue repair or containment of infection; (ii) limited or context-specific fitness costs, allowing structurally stable but abnormal configurations to persist undetected; and (iii) rapid environmental changes that reshape tissue-level selective landscapes, driven by pollutants, endocrine disruptors, or novel diets. Recognizing early-onset organized pathologies as by-products of eco-evolutionary tissue dynamics, rather than as mere developmental errors, reframes their biological significance and opens new therapeutic avenues. Instead of targeting cells exclusively, future strategies could focus on disrupting the functional architecture of pathological tissues and structures, offering novel means to prevent or control early-life diseases shaped by internal selection forces.

IL-22 from enteroendocrine cells promotes early-life gut motility in zebrafish through the microbiota

Abstract

The gut microbiota, immune system, and enteric nervous system interact to regulate adult gut physiology. However, the mechanisms establishing gut physiology during development remain unknown. We report that in developing zebrafish, enteroendocrine cells produced interleukin-22 (IL-22) in response to microbial signals before lymphocytes populated the gut. In larvae, IL-22 shaped the gut microbiota, increasing Lactobacillaceae abundance and ghrelin expression to promote gut motility. Impaired motility and ghrelin expression were restored in il22-/- zebrafish by transfer of microbiota from wild-type zebrafish or by introducing only Lactobacillus plantarum. IL-22-deficient mice also had impaired gut motility and reduced ghrelin expression in early life, indicating a conserved function. Thus, before immune system maturation, enteroendocrine cells regulate early-life gut function by controlling the microbiota through IL-22.

History-indicated cerclage versus ultrasound cervical length screening in women with a history of one extremely preterm birth: A comparative observational cohort study

Abstract

Introduction: In women with a history of one extremely preterm birth, the current literature suggests that ultrasound cervical length screening offers a more favorable risk-benefit ratio than history-indicated cerclage. However, some of the women included in previous studies were at a low risk of cervical insufficiency. Therefore, the efficacy of history-indicated cerclage may have been underestimated. Our objective was to compare history-indicated cerclage with ultrasound cervical length screening in women with a history of one second-trimester loss or extremely preterm birth suggestive of cervical insufficiency.

Material and methods: We conducted a retrospective cohort study comparing two centers with different management strategies for women with a history of one second-trimester loss or extremely preterm birth suggestive of cervical insufficiency. This study was conducted from January 1, 2015 to December 31, 2022 in two French tertiary care maternity units. In the first center, women were offered a cerclage in the first trimester (cerclage center). In the second center, women were offered an ultrasound screening with cerclage only for women with cervical shortening (ultrasound center). To target a population at high risk for cervical insufficiency, we included women with a history of one second-trimester loss or spontaneous preterm birth before 28 weeks of gestation. We excluded women who had any of the following complications in their previous pregnancy: bleeding from placenta previa or placental abruption, intrauterine fetal death, or delivery after invasive prenatal testing. We also excluded women with a history of more than one preterm delivery. Our primary outcome was delivery before 34 weeks. A multivariable analysis was performed.

Results: The rate of delivery before 34 weeks was significantly lower in the cerclage center compared with that in the ultrasound center (26/165 (15.8%) vs. 38/149 (25.5%), p = 0.032). After adjusting for confounding factors, history-indicated cerclage was associated with a twofold decreased risk of delivery before 34 weeks compared with ultrasound cervical length screening (aOR 0.46, 95% CI 0.23-0.95).

Conclusions: In women with a history of one second-trimester loss or extremely preterm birth suggestive of cervical insufficiency, history-indicated cerclage is associated with a lower risk of delivery before 34 weeks compared with ultrasound cervical length screening.

Keywords: cervical insufficiency; history‐indicated cerclage; preterm delivery; second‐trimester fetal loss; ultrasound screening of cervical length.

New PPARG Exons: Cell-Specific Expression of Their RNAs in the Human Placenta

Abstract

Peroxisome proliferator-activated receptor γ (PPARγ), encoded by the PPARG gene on chromosome 3p25.2 in humans, is a ligand-dependent transcription factor that belongs to the nuclear receptor family. In various tissues, PPARγ controls cell differentiation, proliferation, or fusion. Its essential role in the development and functions of the placenta is now well established. To date, the specific functions of its RNA isoforms, encoded by ten exons, in trophoblast biology, including cell fusion and invasion, remain unknown. As translation is mainly regulated by the 5’UTR sequences of mature mRNA, this region was analyzed, and four previously unreported exonic sequences were revealed. Their expressions were confirmed and quantified in villous cytotrophoblasts from term placenta and in chorionic villi from both first-trimester and term placenta. Distinct expression patterns were observed: one exon showed weak expression in placental and chorionic cells, another exhibited stable expression throughout pregnancy, while two exons specific to villous cytotrophoblasts displayed increased expression during the first trimester, suggesting a role in oxygen-responsive mechanisms. Among these, one may be involved in villous trophoblast differentiation. These findings demonstrate that the PPARG gene is composed of 14 exons and is highly regulated depending on cell type and the stage of cell differentiation.

Keywords: 5′UTR exon; PPARG gene; cell-type-specific expression; placenta; pregnancy; trophoblast differentiation.

Prophylactic Treatment of Patent Ductus Arteriosus With Acetaminophen: A Randomized Clinical Trial

Abstract

Importance: Controversies persist about management of the ductus arteriosus by nonsteroidal anti-inflammatory drugs in extremely preterm infants. Acetaminophen (paracetamol) appears to be a promising alternative with possibly fewer adverse effects.

Objective: To evaluate whether prophylactic intravenous acetaminophen started within 12 hours of birth increases survival without neonatal severe morbidities at 36 weeks’ postmenstrual age.

Design, setting, and participants: A double-blind, randomized, placebo-controlled clinical trial was conducted among preterm infants born between 23 weeks 0 days and 28 weeks 6 days of gestation in 43 neonatal intensive care units of 14 European countries between October 2020 (October 2021 for infants born at 23-26 weeks’ gestation, after the phase 2 study identified the optimal dose of acetaminophen) and April 2024. Data analysis was conducted from January to June 2025.

Intervention: In the acetaminophen group, patients born at 27 to 28 weeks’ gestation received a 20-mg/kg loading dose of acetaminophen followed by 7.5 mg/kg every 6 hours for 5 days, and patients born at 23 to 26 weeks’ gestation received a 25-mg/kg loading dose of acetaminophen followed by 10 mg/kg every 6 hours for 5 days. In the placebo group, isotonic sodium chloride was administered.

Main outcomes and measures: The primary outcome was survival without neonatal morbidity evaluated at 36 weeks’ postmenstrual age. The secondary exploratory outcome was ductus arteriosus closure, assessed by echocardiography on day 7.

Results: A total of 778 patients (median [IQR] gestational age, 26 [25-27] weeks; 375 [48.2%] female) were included in the study, with 391 in the acetaminophen group and 387 in the placebo group. Survival without severe morbidities at 36 weeks’ postmenstrual age occurred in 259 infants (66.2%) in the acetaminophen group and 246 (63.6%) in the placebo group (absolute risk difference [ARD], 2.7 [95% CI, -4.0 to 9.3] percentage points; relative risk [RR], 1.04 [95% CI, 0.94 to 1.16]). The ductus arteriosus was considered closed on day 7 in 264 of 371 infants (71.2%) assigned to acetaminophen and 191 of 366 infants (52.2%) assigned to placebo (ARD, 19.0 [95% CI, 12.0 to 25.7] percentage points; RR, 1.36 [95% CI, 1.21 to 1.53]). In the safety analysis, adverse events were not different except for a higher cholestasis rate in the acetaminophen group (25 of 392 infants [6.4%]) vs the placebo group (10 of 386 infants [2.6%]) (ARD, 3.8 [95% CI, 0.9 to 6.9]) percentage points.

Conclusions and relevance: This study found that prophylactic acetaminophen treatment for patent ductus arteriosus did not increase survival without neonatal morbidities.

Trial registration: ClinicalTrials.gov Identifier: NCT04459117.

Probiotic use in French neonatal intensive care units: A nationwide analysis of practice patterns and clinical outcomes

Abstract

Objectives: The primary objective was to describe probiotic exposure in a nationwide cohort of very preterm infants cared for in neonatal intensive care units (NICUs) in France. Secondary outcomes were to describe prescription practices across centers and associated clinical outcomes.

Methods: This retrospective multicentre study included 18,146 infants born at less than 32 weeks of gestation and admitted to NICUs using the same Computer Prescribing Order Entry-Clinical Decision Support system, Logipren®, between January 2019 and December 2023. Linear and logistic regression assessed the association between probiotic exposure and several outcomes, adjusted for sex, gestational age, intrauterine growth restriction, and center-specific effects.

Results: The rate of probiotic exposure in the study cohort was 14.3%, and significantly decreased from 16.2% to 12.7% over the study period. Prescribing practices were highly heterogeneous in terms of: choice of probiotic strains, timing of initiation, duration of treatment, dosing regimens, and pharmaceutical formulations. Limosilactobacillus reuteri DSM 17938 (65.6%) was most frequently used, followed by Lacticaseibacillus (L.) rhamnosus lcr35 (30.0%) and L. rhamnosus GG ATCC 53103 (4.5%). Only one center prescribed the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)-recommended combination (Bifidobacterium (B.) infantis Bb-02, B. lactis Bb-12, and Streptococcus thermophilus TH-4). After multivariate analysis, mortality was significantly lower in the probiotic group (5.2% vs. 7.4%; adjusted odds ratio: 0.20, 95% confidence interval [0.15-0.26]).

Conclusions: Probiotic use in French NICUs remains limited and practice patterns are heterogeneous, with minimal adherence to ESPGHAN recommendations. These results underscore the need for standardized national guidelines and prospective trials.

Keywords: critical care; enteral nutrition; mortality; prescription; supplemental food.

Immunization strategies to prevent malaria in pregnancy – a multistakeholder workshop

Abstract

As part of the ADVANCE-VAC4PM project, the European Vaccine Initiative (EVI) and La Fondation pour la Recherche Scientifique (FORS) co-hosted a hybrid workshop titled « Strategies for using malaria vaccines to prevent malaria in pregnancy (MiP) ». The event brought together researchers, regulators, civil society, global health experts, and policymakers to discuss the need for MiP vaccines and strategies for their development, evaluation, and implementation. Malaria remains a major global health threat, with sub-Saharan Africa bearing the highest burden. Pregnant women (PW) are highly vulnerable, with an estimated 12.4 million affected in 2023. Beyond maternal health effects, a major cause of the MiP-related disease burden is placental malaria (PM), which can cause significant morbidity in newborns. PM risk is greatest in primigravidae and secundigravidae, as immunity develops over successive pregnancies. As existing malaria control strategies remain insufficient, MiP vaccines have the potential to complement them by eliciting immunity comparable to that seen in multigravidae. To be effective, such a vaccine should provide long-lasting immunity and target adolescent girls and women before their first pregnancy. PM vaccine candidates targeting the VAR2CSA antigen (PRIMVAC and PAMVAC) are in development, and existing malaria vaccines preventing infection are being repurposed to prevent MiP. However, limited awareness of MiP-specific burden, weak pharmacovigilance systems, and vaccine hesitancy may hinder future vaccine implementation. Key recommendations highlighted during the workshop included strengthening communication and community engagement strategies, defining relevant efficacy endpoints for pivotal clinical trials, reinforcing pharmacovigilance systems to support safety and real-world effectiveness studies, and planning for early regulatory alignment. Panel discussions emphasized the importance of stakeholder coordination and reduced-dose schedules to support future MiP vaccine programmatic feasibility. The workshop concluded with a call for sustained collaboration and national investment to ensure that MiP vaccines become a viable and effective component of global malaria prevention efforts.

Keywords: Malaria in pregnancy; Placental malaria; Vaccine development; Vaccine implementation.

-Impact of first-trimester preeclampsia screening on perinatal and maternal morbidity: the RANSPRE open multicenter randomized trial

Abstract

Background: Preeclampsia (PE) affects 2 8% of pregnant women and is a leading cause of maternal and perinatal morbidity and mortality. In high risk pregnant women, low dose aspirin (LDA 100 160 mg/day) started before 16 WG reduces the incidence of PE, prematurity, perinatal mortality and low birth weight. First trimester screening of PE allows the identification of a population of pregnant women at high risk of early onset PE and perinatal mortality. It remains unclear whether, on a population scale, the systematic implementation of first trimester screening of PE with treatment of high risk patients by LDA leads to an improvement of maternal and perinatal health.
Methods: This multicenter open randomized controlled trial with two parallel groups will include 14500 pregnant women between 11 14 WG. Eligible women agreeing to participate in the trial will be randomized either to the experimental group with management including screening of PE, or to the control group with usual care without screening of PE. For women in the screening group, the risk of PE will be calculated according to an algorithm combining clinical characteristics, uterine arteries Doppler profile and PlGF concentration. Women with a positive screening test (i.e. predicted risk >1/100) will receive aspirin at 160 mg/day. For women with negative screening, usual pregnancy monitoring without aspirin will be offered. The primary outcome is a composite of severe perinatal morbidity including at least one of the following: perinatal mortality, birth before 34 WG and birth weight < 3rd centile. Secondary endpoints include maternal morbidity and mental health outcomes, and a cost effectiveness evaluation. This study will have a 90% power to show a 50% reduction of the primary outcome in at risk women, expected to represent 10% of the total population in each group, i.e an overall expected 3% frequency of the primary outcome in the intervention group as a whole versus 4% in the control group.
Discussion: This large multicenter randomized trial aims to determine with adequate power if the implementation of first trimester PE screening in all pregnant women would decrease the incidence of perinatal mortality, prematurity before 34 WG and birth weight < 3rd centile.

Opioid-specific brain connectivity dynamics distinguish analgesia from secondary effects: Studies in male mice

Abstract

The µ-opioid receptor (MOP) is a critical pharmaceutical target that mediates both the therapeutic benefits and adverse effects of opioid drugs. However, the large-scale neural circuit dynamics underlying key opioid effects, such as analgesia and respiratory depression, remain poorly understood, hindering the development of safer analgesics. Here, we present a multimodal experimental framework that integrates functional ultrasound imaging through the intact skull with behavioral and molecular analyses to investigate opioid-induced large-scale functional responses and their physiological relevance in awake, behaving male mice. Administration of major opioids-morphine, fentanyl, methadone, and buprenorphine-elicited robust, dose- and time-dependent reorganization of functional brain connectivity (FC) patterns, with magnitude scaling according to MOP agonist efficacy. This opioid-specific functional fingerprint is marked by decreased FC between the somatosensory cortex and hippocampal/thalamic regions and increased bilateral FC within the somatosensory cortex. Notably, this fingerprint was attenuated following tolerance induction and abolished by pharmacological or genetic MOP inactivation. Through power Doppler spectral analysis and lagged correlation measurements, we show that morphine perturbs temporal FC dynamics and the propagation of brain-wide oscillatory activity, disrupting critical-state dynamics. Importantly, we identify a dissociation between fast, transient processes-such as cerebral blood volume changes, locomotion, and respiratory depression-and slower processes driving FC reorganization, analgesia, and sustained MOP activation. This study provides mechanistic insights into opioid-induced network reorganization, establishes FC alterations as a reliable biomarker of opioid efficacy, and offers a framework for advancing the development of analgesic compounds with improved therapeutic windows and reduced side effects.

Keywords: brain imaging; functional connectivity; opioids; pain.

Healthcare professionals’ availability for management of preterm neonates < 29 weeks’ gestation in 12 iNeo neonatal networks

Abstract

Introduction: Availability and expertise of healthcare professional are essential for the quality of care of preterm infants. Objective was to survey different healthcare professionals’ availability for management of preterm neonates <29 weeks’ gestation among neonatal intensive care units (NICU) of 12 population-based neonatal networks.

Methods: Questionnaires were distributed to 608 NICU participating in the International Network for Evaluating Outcomes in Neonates (iNeo). Networks included: Australia/New-Zealand (n= 30), Brazil (n=20), Canada (n=32), Finland (n=5), France (n=70), Israel (n=26), Japan (n=292), Poland (n=56), Spain (n=55), Sweden (n=9), Switzerland (n=9) and Tuscany (n=4). Questions focused on availability of physicians, nurses and additional healthcare professionals in 2023.

Results: A total of 382 (63%) NICU responded. The 24/7 availability of healthcare professionals varied within and between networks and overall was reported to be 66% for neonatologists, 55% for neonatal fellows, 62% for pediatric residents and 55% for nurse practitioners. Nurse-to-patient ratios were most commonly 1:1 for complex critical care infants (53%) and 1:2 for intensive care infants (48%). Low 24/7 availability was reported for respiratory therapists and pharmacists.

Conclusions: Marked variations exist in health care professionals’ availability, which might be associated with NICU organization and management of infants <29 weeks’ gestation. While majority of NICU have reported 24/7 availability of neonatologists, the availability of other healthcare professionals was inconsistent. Nurse-to-patient ratio has improved. Further evaluation is needed to understand how these variations are associated with outcomes of extremely preterm infants and to optimize resource utilization.